As the global population enters an aging phase, chronic diseases account for the main burden of illness, with cardiovascular and cerebrovascular diseases, malignant tumors, etc., becoming leading causes of death. While seeking treatment, patients hope to improve their quality of life despite their illnesses, thus driving continuous growth in the demand for innovative drugs.
According to the new drug development process, pharmaceutical R&D outsourcing service (CRO) companies provide services ranging from drug discovery to non-clinical and clinical stages. These services include but are not limited to drug discovery, pharmacology and efficacy, pharmacokinetics and toxicology, bioanalysis, clinical trial monitoring, site management (SMO), data management, and statistical analysis.
Based on long-term tracking of the pharmaceutical R&D outsourcing service market, Frost & Sullivan has released the 'Research Report on the Pharmaceutical R&D Outsourcing Service Market'.
